Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert R Henry

Showing results (21-30 of 155) with videos related to

Pageof 16
Sort By:
Postgraduate Medicine|May 14, 2010
Managing type 2 diabetes: balancing HbA1c and body weightAnnie A Mavian, Stephan Miller, Robert R Henry
Diabetes Research and Clinical Practice|August 2, 2011
Presidents' statement on WHO recommendation on HbA1c for diabetes diagnosisJean Claude Mbanya, Robert R Henry, Ulf Smith
Current Cardiology Reports|January 15, 2013
Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetesPam R Taub, Erin Higginbotham, Robert R Henry
Current Diabetes Reports|October 6, 2004
Diabetes and obesity: medical diseases, surgical cure?Vanita R Aroda, Michelle K Savu, Robert R Henry
Molecular Biology Reports|January 7, 2021
Impaired capillary tube formation induced by elevated secretion of IL8 involves altered signaling via the CXCR1/PI3K/MMP2 pathwayYifat Amir Levy, Theodore P Ciaraldi, Robert R Henry
Frontiers in Physiology|February 11, 2020
Myokine Regulation of Insulin Secretion: Impact of Inflammation and Type 2 DiabetesAlexander J Ryan, Theodore P Ciaraldi, Robert R Henry
Diabetes Care|November 26, 2015
Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to BedsideSunder Mudaliar, David Polidori, Brian Zambrowicz, et al.
Expert Review of Endocrinology & Metabolism|February 21, 2019
Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literatureCourtney Aavang Tibble, Tricia Santos Cavaiola, Robert R Henry
Diabetes Care|May 23, 2013
Signals and noise in drug safety analyses: the incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilanceWilliam T Cefalu, Julio Rosenstock, Robert R Henry, et al.
Diabetes Care|July 29, 2003
Adiponectin: more than just another fat cell hormone?Manju Chandran, Susan A Phillips, Theodore Ciaraldi, et al.
Pageof 16

Showing results (21-30 of 155) with videos related to

Sort By:
Pageof 16
Postgraduate Medicine|May 14, 2010
Managing type 2 diabetes: balancing HbA1c and body weightAnnie A Mavian, Stephan Miller, Robert R Henry
Diabetes Research and Clinical Practice|August 2, 2011
Presidents' statement on WHO recommendation on HbA1c for diabetes diagnosisJean Claude Mbanya, Robert R Henry, Ulf Smith
Current Cardiology Reports|January 15, 2013
Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetesPam R Taub, Erin Higginbotham, Robert R Henry
Current Diabetes Reports|October 6, 2004
Diabetes and obesity: medical diseases, surgical cure?Vanita R Aroda, Michelle K Savu, Robert R Henry
Molecular Biology Reports|January 7, 2021
Impaired capillary tube formation induced by elevated secretion of IL8 involves altered signaling via the CXCR1/PI3K/MMP2 pathwayYifat Amir Levy, Theodore P Ciaraldi, Robert R Henry
Frontiers in Physiology|February 11, 2020
Myokine Regulation of Insulin Secretion: Impact of Inflammation and Type 2 DiabetesAlexander J Ryan, Theodore P Ciaraldi, Robert R Henry
Diabetes Care|November 26, 2015
Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to BedsideSunder Mudaliar, David Polidori, Brian Zambrowicz, et al.
Expert Review of Endocrinology & Metabolism|February 21, 2019
Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literatureCourtney Aavang Tibble, Tricia Santos Cavaiola, Robert R Henry
Diabetes Care|May 23, 2013
Signals and noise in drug safety analyses: the incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilanceWilliam T Cefalu, Julio Rosenstock, Robert R Henry, et al.
Diabetes Care|July 29, 2003
Adiponectin: more than just another fat cell hormone?Manju Chandran, Susan A Phillips, Theodore Ciaraldi, et al.
Pageof 16